Aneta Zachova is a journalist at Eurasia Review. She focuses on energy and mining, with a keen interest in public health, healthcare administration, and consumer health topics. Aneta's work has been featured in notable publications including LRT and EURACTIV.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Czech Republic (National)
Not enough data
Aneta Zachova's coverage focuses on government announcements and legal policy regulations, specifically in the context of the Czech Republic and its relations with other countries. She covers topics related to politics, migration, and international relations at both national and European levels.
If you are considering reaching out to Aneta with a pitch or as a potential source, ensure that your content is closely aligned with political developments within the Czech Republic or EU affairs. Expert commentary on government policies, legal regulations, or geopolitical events would likely be well received by her based on her coverage attributes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Analysis shows Czech patients now wait an average of 659 days for innovative therapies after they are approved at EU level
While Czech officials support stronger cooperation between EU countries, they insist that governments should retain control over pricing and reimbursement decisions
By: Aneta Zachová
Czech innovative business estimates that sponsor-funded clinical trials saved the Czech healthcare system around €85 million in 2025
Between 450 and 700 jobs could be lost as funding cut to Czech television and radio
Czech patients with stable chronic conditions will soon be able to obtain more than 1,200 reimbursed medicines directly from their general practitioner
Babiš insists he complies with both Czech and EU law PRAGUE – EU prosecutors have opened a criminal investigation into Czech Prime Minister
Ireland's long-standing support for pharmaceutical research and innovation makes it well-positioned to drive progress on Europe's life sciences agenda, industry notes
Spain's proposal on faster access to innovative medicines is drawing cautious support, but Czechia, Greece and Sweden emphasise a clear distinction between medicine access and pricing
Czechia is moving its most complex cancer operations into specialised centres, joining a wider EU push to concentrate difficult procedures where hospitals can build the volume and expertise that improve survival
Companies can't be expected to invest heavily in electrification while they face high electricity prices, said the four countries
